Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Drug Profile

Research programme: neurodegenerative disorders therapeutics - BioArctic Neuroscience

Alternative Names: AD 1503; AD-0802; AD-1502; AD-2203; AE-1501; BAN-0805; BAN-2203; BAN-2502; BAN2401 back-up; PD-0805

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioArctic Neuroscience
  • Developer BioArctic
  • Class Antiparkinsonians; Monoclonal antibodies; Neuroprotectants; Vaccines
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 07 Aug 2018 BioArctic obtains exclusive rights within its collaboration with Eisai to develop antibodies for Alzheimer's disease
  • 14 May 2018 BioArctic and Uppsala University extends research collaboration for antibody technology to increase passage across the blood-brain barrier for neurodegenerative diseases
  • 07 Mar 2018 Preclinical development for Alzheimer's disease and Parkinson's disease is ongoing (BioArctic pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top